What are the most frequent adverse reactions associated with AmBisome therapy and how do they compare with those of amphotericin B deoxycholate?
The following adverse events are based on the results of a randomized double-blind, multi-center study (Study 94-0-002) in febrile, neutropenic patients. The study involved 592 adult patients (295 treated with AmBisome and 297 treated with amphotericin B deoxycholate) and 95 pediatric patients (48 treated with AmBisome and 47 treated with amphotericin B deoxycholate). AmBisome and amphotericin B were infused over two hours.